PLx Pharma (PLXP) Tops Q2 EPS by 4c

Go back to PLx Pharma (PLXP) Tops Q2 EPS by 4c

PLx Pharma Inc. Reports Second Quarter 2022 Results and Provides Business Update

August 12, 2022 6:50 AM EDT

- Initiates Evaluation of Strategic Alternatives to Enhance Stockholder Value

- Reports Positive Results of VAZALORE® 81 mg Patient Experience Survey

- Streamlines Sales & Marketing Plan

Total Net Sales of $0.5 Million, Including $0.4 Million of Unfavorable Adjustments for Additional Trade Allowances and Incremental Sales Returns Reserves in Second Quarter of 2022Total Operating Expenses Were Lower by $4.9 Million in Second Quarter of 2022 vs. Q1 2022GAAP Net Loss of ($0.43) Per Diluted Share in... More